A Novel Non-Invasive Acoustic Diagnostic for the Diagnosis of Coronary Artery Disease The CAD-det Validation Study
Launched by AUSCULSCIENCES CANADA INC. · Sep 18, 2020
Trial Information
Current as of May 14, 2025
Unknown status
Keywords
ClinConnect Summary
This is a prospective multi-center clinical trial. Using the CAD-det, acoustic and electrical cardiac data will be collected from participants with intermediate pretest probability of CAD who are referred to invasive coronary angiography (ICA). The CAD-det recording will be administered prior to the scheduled ICA procedure. The data collected by CAD-det will be processed using AusculSciences' Data Analysis Application (DAA) to produce a patient's indication for CAD.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Stable
- • 2. \>/= 19 years old
- • 3. Suspected obstructive CAD
- • 4. Referred to ICA
- Exclusion Criteria:
- • 1. Documented CAD or coronary revascularization
- • 2. Age \< 19 years old
- • 3. Acute coronary syndromes
- • 4. Congenital heart disease or heart transplantation
- • 5. Dextrocardia
- • 6. Uncontrolled irregular heart rhythm (atrial arrhythmia (fibrillation, flutter) or frequent PACs or PVCs (\>10/minute))
- • 7. Resting heart rate \> 110 bpm
- • 8. Known hemodynamically-significant valvular heart disease, audible diastolic murmurs, or hypertrophic or non-ischemic cardiomyopathy
- • 9. Chest wall deformity or wounds in adhesive application areas
- • 10. Pregnancy
- • 11. Unwillingness or inability to provide informed consent or to comply with the study protocol
About Ausculsciences Canada Inc.
AuscultSciences Canada Inc. is a leading clinical trial sponsor dedicated to advancing healthcare through innovative research and development. Specializing in the evaluation of novel therapeutic interventions, the company leverages cutting-edge technology and a robust network of clinical sites to facilitate high-quality, patient-centered studies. Committed to regulatory compliance and ethical standards, AuscultSciences Canada Inc. collaborates with healthcare professionals and stakeholders to generate reliable data that drives informed decision-making in the medical community. With a focus on improving patient outcomes, the organization seeks to contribute significantly to the advancement of medical science and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ottawa, Ontario, Canada
Ottawa, Ontario, Canada
Patients applied
Trial Officials
Ben Chow, MD
Principal Investigator
Ottawa Heart Institue Research Foundation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials